Haemonetics prices $600M 2.50% convertible notes due 2029; to repurchase $200M of 2026 notes

HAEMONETICS CORP

$600M 2.50% convertible senior notes due 2029 priced; initial conversion price ~$117.12/share (30% premium over $90.09 closing).
Concurrently repurchasing $200M aggregate principal of 0.00% 2026 notes for $185.5M cash in privately negotiated transactions.
Net proceeds estimated ~$584.8M; to repay $230M revolver, pay ~$75.6M for capped calls, and for general purposes.
Capped call transactions entered to offset dilution, with initial cap price $180.18/share (~100% premium).
Initial purchasers granted option to buy up to additional $100M principal amount of notes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.